カナダ - 英語 - Health Canada

dr reddy's laboratories ltd - fondaparinux sodium - solution - 10mg - fondaparinux sodium 10mg - direct factor xa inhibitors

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

aspen pharma trading limited - fondaparinux sodium - solution for injection - fondaparinux

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - fondaparinux sodium, quantity: 2.5 mg - injection, solution - excipient ingredients: sodium chloride; water for injections - arixtra is indicated for the prevention of venous thromboembolic events (vte) in patients undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee or hip replacement surgery.,arixtra is indicated for the prevention of venous thromboembolic events (vte) in patients undergoing abdominal surgery who are at risk of thromboembolic complications.,arixtra is indicated for the treatment of acute deep venous thrombosis (dvt) and acute pulmonary embolism (pe).,arixtra is indicated for the treatment of unstable angina or non-st segment elevation myocardial infarction (ua/nstemi) for whom urgent (<120 min) invasive management (pci) is not indicated.,arixtra is indicated for the treatment of st segment elevation myocardial infarction (stemi) in patients who are managed without any form of initial reperfusion therapy.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - fondaparinux sodium, quantity: 2.5 mg - injection, solution - excipient ingredients: sodium chloride; water for injections - fondaparinux is indicated for the prevention of venous thromboembolic events (vte) in patients undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee or hip replacement surgery.,fondaparinux is indicated for the prevention of venous thromboembolic events (vte) in patients undergoing abdominal surgery who are at risk of thromboembolic complications.

イスラエル - 英語 - Ministry of Health

padagis israel agencies ltd, israel - fondaparinux sodium - solution for injection - fondaparinux sodium 5 mg / 1 ml - fondaparinux - fondaparinux - prevention of venous thromboembolic events (vte) in adults undergoing major orthopaedic surgery of the lower limbs such as hip fracture major knee surgery or hip replacement surgery. prevention of venous thromboembolic events (vte) in adults undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications such as patients undergoing abdominal cancer surgery. prevention of venous thromboembolic events (vte) in adults medical patients who are judged to be at high risk for vte and who are immobilised due to acute illness such as cardiac insufficiency and/or acute respiratory disorders and/or acute infectious or inflammatory disease. treatment of unstable angina or non-st segment elevation myocardial infarcton (ua/nstemi) in adults for whom urgent ( < 120 mins) invasive management (pci) is not indicated . treatment of st segment elevation myocardial infarction (stemi) in patients who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy.

イスラエル - 英語 - Ministry of Health

padagis israel agencies ltd, israel - fondaparinux sodium - solution for injection - fondaparinux sodium 12.5 mg/ml - fondaparinux - fondaparinux - treatment of adults with acute deep vein thrombosis (dvt) and treatment of acute pulmonary embolism (pe), except in haemodynamically unstable patients or patients who require thrombolysis or pulmonary embolectomy.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - fondaparinux sodium, quantity: 10 mg - injection, solution - excipient ingredients: water for injections; sodium chloride - arixtra is indicated for the prevention of venous thromboembolic events (vte) in patients undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee or hip replacement surgery. arixtra is indicated for the prevention of venous thromboembolic events (vte) in patients undergoing abdominal surgery who are at risk of thromboembolic complications. arixtra is indicated for the treatment of acute deep venous thrombosis (dvt) and acute pulmonary embolism (pe

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - fondaparinux sodium, quantity: 7.5 mg - injection, solution - excipient ingredients: sodium chloride; water for injections - arixtra is indicated for the prevention of venous thromboembolic events (vte) in patients undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee or hip replacement surgery. arixtra is indicated for the prevention of venous thromboembolic events (vte) in patients undergoing abdominal surgery who are at risk of thromboembolic complications. arixtra is indicated for the treatment of acute deep venous thrombosis (dvt) and acute pulmonary embolism (pe

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - fondaparinux sodium, quantity: 5 mg - injection, solution - excipient ingredients: water for injections; sodium chloride - arixtra is indicated for the prevention of venous thromboembolic events (vte) in patients undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee or hip replacement surgery. arixtra is indicated for the prevention of venous thromboembolic events (vte) in patients undergoing abdominal surgery who are at risk of thromboembolic complications. arixtra is indicated for the treatment of acute deep venous thrombosis (dvt) and acute pulmonary embolism (pe).

イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

dr reddy's laboratories (uk) ltd - fondaparinux sodium - solution for injection - 5mg/1ml